bezuclastinib (PLX9486) / Daiichi Sankyo, Cogent Biosci  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bezuclastinib (PLX9486) / Cogent Biosci
2021-001010-10: A Study of CGT9486 in Patients with Advanced Systemic Mastocytosis Estudio de CGT9486 en pacientes con mastocitosis sistémica avanzada

Ongoing
2
140
Europe
CGT9486, [na], Tablet
Cogent Biosciences, Inc., Cogent Biosciences, Inc., COGENT BIOSCIENCES, INC
Advanced Systemic Mastocytosis (AdvSM) Mastocitosis Sistémica Avanzada (MSav), Mastocytosis Mastocitosis, Diseases [C] - Cancer [C04]
 
 
NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Recruiting
2
40
US
Bezuclastinib in combination with sunitinib
Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group
Gastrointestinal Stromal Tumors, GIST
06/26
06/27
Summit, NCT05186753: () A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Recruiting
2
138
Europe, Canada, US, RoW
Bezuclastinib Tablets (Formulation A), CGT9486, PLX9486, Bezuclastinib Tablets (Formulation B), Placebo Tablets
Cogent Biosciences, Inc.
SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
11/24
11/26
CGT9486-20-201, NCT04996875: (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Recruiting
2
140
Europe, Canada, US, RoW
bezuclastinib, CGT9486, PLX9486
Cogent Biosciences, Inc.
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
01/25
09/25

Download Options